Tender Details

Country: USA
Summary: Facilitating T1 Translational Aging Research: Preclinical And Early Phase Human Studies (Ug3/Uh3 Clinical Trial Optional)
UST Ref No: 109377203
Deadline: 10 Jan 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: RFA-AG-25-027
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
This Notice Of Funding Opportunity (Nofo) From The National Institute On Aging (Nia) Invites Applications On T1 Translational Aging Research (I.E., Bench To Bedside) Which Focus On Advancing New Therapeutics From Preclinical Stages To First-In-Human (Fih) Trials For Aging-Related Conditions Such As Sarcopenia, Heart Failure With Preserved Ejection Fraction (Hfpef), And Deficits Such As Immunosenescence. The Nofo Will Specifically Support Two Categories Of Milestone-Driven Projects: 1) Traditional De Novo Drug Development (I.E., New Chemical/Molecular Entities) With Three Specific Entry Points To The Translational Pipeline (I.E., Screening Through Preclinical Validation, Hit To Lead Through Ind, Or Late-Stage Preclinical Development Through Fih Studies), And 2) Data-Driven Computational Drug Repurposing Strategies With Subsequent Validation Of Predictions And Generation Of Proof-Of-Concept Data In Pertinent Animal Models And/Or In Human In Vitro Studies.For The Purposes Of This Nofo, Drug Repurposing (Also Known As Drug Repositioning, Reprofiling Or Re-Tasking) Refers To Approaches For Identifying Alternative Uses For Fda-Approved Drugs Or Investigational Therapeutics Which Are Beyond The Scope Of The Original Intended Clinical Indication. The Types And Scale Of Proposed Translational Research Activities In The Projects Are Anticipated To Vary And Will Depend On Whether The Project Focuses On Traditional Drug Development Pathways Or Involves Drug Repurposing. The Ug3 Phase Of ...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Facilitating T1 Translational Aging Research: Preclinical And Early Phase Human Studies (Ug3/Uh3 Clinical Trial Optional) - USA Tender

The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Facilitating T1 Translational Aging Research: Preclinical And Early Phase Human Studies (Ug3/Uh3 Clinical Trial Optional). This tender is published on USARFP under UST Ref No: 109377203 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-10.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.